MiNK Therapeutics (INKT) Cash & Equivalents (2020 - 2026)

MiNK Therapeutics has reported Cash & Equivalents for 7 years, with the latest figure at $9.5 million in Q1 2026.

• Quarterly Cash & Equivalents rose 197.68% year-over-year to $9.5 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $9.5 million (up 197.68% YoY) and the FY2025 annual result came in at $13.4 million, up 191.9% from the prior year.
• Cash & Equivalents declined to $9.5 million in Q1 2026 per INKT's latest filing, from $13.4 million in the prior quarter.
• Over five years, Cash & Equivalents peaked at $34.7 million in Q1 2022 and troughed at $1.7 million in Q2 2025.
• A 5-year average of $12.2 million and a median of $9.5 million in 2025 frame the typical range for Cash & Equivalents.
• The sharpest annual moves came in 2022 and 2023: Cash & Equivalents soared 2848.15% in 2022, then sank 82.85% in 2023.
• Over 5 years, Cash & Equivalents stood at $19.6 million in 2022, then tumbled by 82.85% to $3.4 million in 2023, then surged by 35.93% to $4.6 million in 2024, then soared by 191.9% to $13.4 million in 2025, then slipped by 28.7% to $9.5 million in 2026.
• According to Business Quant data, Cash & Equivalents over the past three periods registered $9.5 million, $13.4 million, and $9.5 million for Q1 2026, Q4 2025, and Q3 2025 respectively.